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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy and safety of ghrelin on improving food intake, body composition and survival in patients with cachexia associated
with cancer.
B A C K G R O U N D
This protocol is partly based on suggested wording from the Pain,
Palliative and Supportive Care Review Group (PaPaS CRG).
Description of the condition
Cancer and its co-morbidities, like cancer cachexia, have afflicted
humans for centuries and still continue to be a major public health
problem. Patients suffering from cancer are amongst the most
malnourished of all the patient groups (Ryan 2016). It has been
estimated that cachexia affects 60% to 80% of all advanced cancer
patients (Baracos 2011) and more than 30% of patients die due
to cachexia (von Haehling 2012). Cancer cachexia is commonly
associated with decreased life expectancy and poor quality of life
(Utech 2012).
Cancer cachexia is defined as “a multifactorial syndrome charac-
terised by an ongoing loss of skeletal muscle mass (with or with-
out loss of fat mass) that cannot be fully reversed by conven-
tional nutritional support and leads to progressive functional im-
pairment” (Fearon 2011). Cachexia syndrome can develop pro-
gressively, through stages of pre-cachexia to cachexia to refrac-
tory cachexia (Fearon 2011). The incidence of cancer cachexia
varies according to tumor type (Teunissen 2007; Tisdale 2009;
Sun 2015). The prevalence of cachexia is highest in people with
pancreatic cancer (88.9%), followed by gastric cancer (76.5% to
87%) and esophageal cancer (52.9%) (Sun 2015; Tisdale 2009).
The frequency of weight loss is lowest in patients with breast can-
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cer, sarcomas, non-Hodgkin’s lymphoma and acute nonlympho-
cytic leukemia (Teunissen 2007; Tisdale 2009). Cachexia can be a
presenting symptom in a majority of patients with advanced can-
cer; mainly those with hepatic, lung, or bone metastasis and pri-
mary cancers of the lung, cervix or head and neck (Mendes 2015).
Although certain tumor types are more commonly associated with
cachexia, even with the same tumor type there are variations in
the extent to which patients exhibit cachexia (Tisdale 2009).
During the last few decades extensive research has been carried
out to understand the complex pathophysiology of cachexia as-
sociated with cancer. Anorexia, anaemia, asthenia, inflammation,
altered hormonal homeostasis, energy imbalance, and several can-
cer-related metabolic changes (like negative protein balance and
increased lipolysis) leading to significant weight loss have been
attributed to the pathogenesis of cancer cachexia (Mendes 2015;
Penna 2010; Stephens 2008). Therapies for cancer, such as che-
motherapy, surgery and radiotherapy, also cause anorexia, mus-
cle atrophy and weight loss (Chen 2015; Garcia 2005; Tisdale
2009). Deregulation of control of energy expenditure and hunger/
satiety by the hypothalamus promotes cachexia in cancer patients
(Mendes 2015). A discrepancy between anabolic and catabolic
pathways mediated by chronic inflammation can cause muscle
wasting in patients with cancer cachexia (Madeddu 2015a). De-
pletion of adipose tissue as well as skeletal muscle mass with rel-
ative preservation of non-muscle protein compartment can con-
tribute to weight loss in cancer patients (Tisdale 2009). Stud-
ies suggest that the tumour cells secrete certain humoral factors
which promote central and peripheral-mediated cancer cachexia
(Stewart 2006). Cachectic factors (like activin and proteolysis-in-
ducing factor) secreted by the tumour cells decrease the synthesis
and increase the breakdown of muscle proteins, and thereby in-
duce sarcopenia (Stewart 2006). Excretion of cytokines and lipid-
mobilising factors may contribute to depletion of adipose tissue
(Stewart 2006). Tumor cells secrete pro-inflammatory factors that
promote cachexia by signaling anorexia, muscle wasting and atro-
phy of white adipose tissue (WAT). The release of inflammatory
cytokines like TNF-α (cachexin or cachectin), interferon gamma,
interleukin-6 and angiotensin II can also have a role in cancer
cachexia (Tisdale 2009).
As cachexia progresses, wasting of skeletal muscles limits mobil-
ity and thereby leads to poor quality of life which in turn pushes
cancer patients towards isolation and depression (Stewart 2006;
Watanabe 1996; Windsor 1988). Not only patients, but also fam-
ily members - especially caregivers - and healthcare professionals
often suffer from depression as they try to palliate cancer patients’
symptoms (Reid 2012). Although cancer cachexia is associated
with increased mortality and poor quality of life, treatment op-
tions for the condition are limited (Penna 2016). As the condition
is associated with complex pathophysiological processes, therapies
with potential orexigenic, anabolic and anti-inflammatory effects
should be targeted to counter this condition.
Description of the intervention
The approach to treatment for cancer cachexia is multimodal
and includes nutritional support, pharmacological treatments, and
non-pharmacological therapies like physical training (Madeddu
2015a). Caloric supplementation or appetite stimulants likemege-
strol acetate, medroxyprogesterone acetate (MPA), cyprohepta-
dine, marijuana, and corticosteroids such as dexamethasone, pred-
nisolone and methylprednisolone have been used for enhancing
appetite in cancer patients (Fearon 2011; Tisdale 2009). However,
these interventions have limited efficacy. No definitive pharmaco-
logical treatment is available to address the relevant components
of the syndrome (Esposito 2015).
Ghrelin, a novel orexigenic gut hormone, is primarily secreted by
the endocrine X/A-like cells of the stomach mucosa and also by
intestinal mucosa, arcuate nucleus of the hypothalamus, pituitary
gland, pancreatic islets, and other tissues (Khatib 2015b). Studies
have shown that this 28-amino acid peptide hormone is an en-
dogenous ligand for the growth hormone secretagogue receptor
and can be a potential therapeutic agent for cachexia-associated
cancer (Chen 2015; Garcia 2015; Pietra 2014; Tsubouchi 2014;
Zhang 2015). It has shown promising results in randomised clini-
cal trials (Garcia 2007; Garcia 2013; Garcia 2015; Khatib 2014b;
Khatib 2014e; Madeddu 2015b). Ghrelin has the potential to in-
crease body weight and body composition through increased ap-
petite, increased growth hormone (GH) secretion and prevention
of muscle catabolism, which suggests that ghrelin could be an
effective treatment for cancer anorexia (DeBoer 2007; Fujitsuka
2011; Garcia 2005; Garcia 2013; Khatib 2014a; Khatib 2014d;
Khatib 2014f; Khatib 2015b; Klok 2007; Neary 2004; Tsubouchi
2014; Wren 2001). Ghrelin is well tolerated with no reported side
effects (Akamizu 2010; Khatib 2015a; Neary 2004).
Ghrelin agonists are being developed and tested for the treatment
of anorexia/cachexia. Anamorelin, a first-in-class, potent orally-
active and highly-specific ghrelin receptor agonist, increases food
intake, body weight and lean body mass (Northrup 2013; Pietra
2014). It is well tolerated with no dose-limiting toxicities (Zhang
2015). Anamorelin treatment for 12 weeks had a favourable clini-
cal response profile in patients with cancer anorexia-cachexia syn-
drome in one study (Garcia 2015). Administration of RC-1291, a
ghrelin mimetic, in cachectic cancer patients increased lean body
mass in another study (Garcia 2007); it represents a new class of
drug for patients with cancer cachexia.
How the intervention might work
Although the mechanisms of action of ghrelin have not been fully
elucidated, an increase in appetite and decrease in energy expen-
diture via hypothalamic effects (Fujitsuka 2014; Garcia 2013;
Murphy 1998); promotion of anabolic activity (Chen 2015); de-
crease in inflammation (Dixit 2004; Tsubouchi 2014); an increase
in growth hormone (Garcia 2009; Khatib 2014a; Khatib 2014d;
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Khatib 2014f); control of gastrointestinal motility (Fujino 2003);
and direct effects in adipose tissue (Kos 2009) and skeletal muscle
(Porporato 2013; Tsubouchi 2014) have been proposed.
Ghrelin and synthetic ghrelin receptor agonists cause weight gain
by increasing food intake and by food intake-independent mecha-
nisms (Garcia 2013; Sugiyama 2012; Tschop 2000). Ghrelin pro-
motes weight gain and lean body mass via anti-inflammatory ac-
tion and effects involving orexigenic neuropeptides (DeBoer 2007;
Khatib 2014c; Khatib 2015b). Animals treated with ghrelin ex-
hibit a decreased expression of IL-1 receptor-I transcript in the
hypothalamus and brainstem and an increased expression of orex-
igenic peptides and neuropeptide Y (NPY) in the hypothalamus
(DeBoer 2007; Tisdale 2009). Administration of ghrelin prevents
muscle atrophy by down-regulating inflammation and activating
protein kinase B (a protein kinase that plays a key role in apoptosis,
cell proliferation, and cell migration), myogenin (a transcription
factor involved in myogenesis and repair) and myoD (a protein
that plays a major role in regulating muscle differentiation) (Chen
2015). Both acytylated and unacytylated ghrelin blocks skele-
tal muscle atrophy in a growth hormone-independent manner
(Porporato 2013). In vitro studies have demonstrated that ghrelin
may regulate mesenchymal cell development by stimulating myo-
genesis (Zhang 2007). Cells expressing ghrelin have demonstrated
a significant increase in the differentiation of premyocytes into
myocytes (Zhang 2007). Ghrelin inhibits the production and pre-
vents the increase of pro-inflammatory cytokines released by the
tumour cells (Chen 2015; Dixit 2004; Tsubouchi 2014). Activa-
tion of the ghrelin receptor in the central nervous system releases
GH which regulates insulin-like growth factor-1 (IGF-1) (Khatib
2014f; Khatib 2014a; Velloso 2008). GH/IGF-1 axis acts directly
on bone, muscle and fat tissue and also indirectly by producing
anti-cachectic cytokines and muscle-restricted insulin-like growth
factor-1 (mIGF-1) (Fuoco 2015). Since GH secretagogue recep-
tors (GHS-R) are expressed in vagal afferent neurons, the gastric
vagus nerve is involved in the effect of ghrelin on food intake and
GI motility (Date 2002). Gastric ghrelin signaling via vagal affer-
ents suppresses the activity of the sympathetic nerves and increases
the discharge of both the gastric and the vagus efferent nerves
(Fujitsuka 2009). Ghrelin also promotes fasted motor activity by
activating the NPY neurons in the brain (Fujino 2003). Anamore-
lin increases GH, IGF-1 and body weight with good tolerability
and selectivity (Garcia 2009). Oral administration of rikkunshito
increases plasma acyl ghrelin levels in humans, mice, rats and dogs
(Fujitsuka 2009; Fujitsuka 2011; Takeda 2008). It may be a viable
treatment modality for cancer-associated cachexia.
Why it is important to do this review
Despite the high prevalence of cancer cachexia, effective thera-
pies are still limited and no definitive pharmacological treatment
is available to address the relevant components of this syndrome
(Esposito 2015). There is a strong need formore effective appetite-
stimulatory therapies for patientswith this condition. Several stud-
ies have demonstrated positive and encouraging effects of ghre-
lin or GH secretagogues (GHS) in patients with cancer cachexia
(Esposito 2015; Garcia 2007; Garcia 2013; Molfino 2014; Neary
2004). However, the safety and efficacy of ghrelin for cancer-as-
sociated cachexia have not been systematically reviewed. There is
a need to synthesise the evidence for patients, practitioners and
policy makers to decide whether ghrelin can be incorporated in
the management of cachexia associated with cancer and, if data
permit, to explore the optimal drug programme for this group of
patients. Therefore, systematic evaluation of the role of ghrelin in
the treatment of cancer cachexia is warranted.
O B J E C T I V E S
To assess the efficacy and safety of ghrelin on improving food
intake, body composition and survival in patients with cachexia
associated with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) with un-
blinded or blinded assessment of outcomes. Full journal publica-
tion is required, with the exception of extended abstracts of oth-
erwise unpublished clinical trials. We will exclude short abstracts
(usually meeting reports), non-randomised studies, studies of ex-
perimental pain, case reports, and clinical observations.’
Types of participants
We will include cachexic adults of 18 years and over with a histo-
logical or clinical diagnosis of cancer; or meeting any of the inter-
national criteria for cancer cachexia (Bozzetti 2009; Fearon 2006;
Fearon 2011). Both inpatients and outpatients with any stage of
cancer irrespective of gender or race will be considered for inclu-
sion. We will include patients in any healthcare setting (including
hospice, hospital, oncology centre or community).
Types of interventions
We will include studies in which the intervention is the admin-
istration of ghrelin in any form, at any dose, at any frequency,
by any route and for any duration, administered for improving
food intake, body composition and survival, compared to placebo
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or any active comparator (such as appetisers, nutritional supple-
ments, etc.).
The following comparisons will be made in the review:
1. Ghrelin versus placebo;
2. Ghrelin versus no treatment;
3. Ghrelin versus alternative experimental treatment modality
(like appetisers, nutritional supplements, etc);
4. Ghrelin in combination with other treatments versus
ghrelin treatment alone;
5. Ghrelin treatment versus ghrelin analogues/ghrelin
mimetics (anamorelin, ipamorelin, eganamorelin, hexarelin,
MK-677, etc.) or ghrelin potentiators/enhancers (rikkunshito).
Types of outcome measures
Primary outcomes
1. Change in food intake as difference between baseline and
the end of treatment. We will express this outcome as a
dichotomous variable (number of patients who experienced an
increase in food intake) or a continuous variable (actual change
in food intake).
2. Change in body weight as difference between baseline and
at the end of treatment. We will express this outcome as a
dichotomous variable (number of patients who experienced
change in body weight) or a continuous variable (actual change
in body weight).
3. Adverse events as the number of patients who suffered an
event described as an adverse event by the authors of the studies.
Secondary outcomes
1. Change in survival measured as increase in survival in days.
We will use hazard ratios for how many times more (or less)
likely a participant is to suffer the event at a particular point in
time if they receive ghrelin rather than the control intervention.
2. Change in body composition (lean body mass, fat mass) as
difference between baseline and the end of treatment. We will
express this outcome as a dichotomous variable (number of
patients who experienced change in body weight) or a
continuous variable (actual change in body composition).
3. Plasma ghrelin levels as difference between baseline and the
end of treatment. We will express this outcome as a dichotomous
variable (number of patients who experienced increase in plasma
ghrelin levels) or a continuous variable (actual change in plasma
ghrelin levels).
4. Change in the Quality of Life (QoL) using Health-Related
Quality of Life (HRQoL) (CDC 2016).
Reporting of these outcome measures will not form part of the
criteria for including studies in a review.
Search methods for identification of studies
Electronic searches
We will search the following databases without language restric-
tions.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (via the Cochrane Library).
• MEDLINE (via Ovid).
• EMBASE (via Ovid).
Medical subject headings (MeSH) or equivalent and text-word
terms will be used. Full text translations of all relevant non-English
articles will be obtained. Searches will be tailored to individual
databases. The search strategy for MEDLINE can be found in
Appendix 1.
Searching other resources
We will search the metaRegister of controlled tri-
als (mRCT) (www.controlled-trials.com/mrct), National Cancer
Institute (http://www.cancer.gov/clinicaltrials), clinicaltrials.gov (
www.clinicaltrials.gov), and the WHO International Clinical Tri-
als Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)
for ongoing trials. We will also search ClinicalStudyResults.org (
www.clinicalstudyresults.org) for clinical trials. In addition, ref-
erence lists of reviews and retrieved articles will be checked for
additional studies, and citation searches will be performed on key
articles. Authors will be contacted where necessary for additional
information. Wewill perform handsearching of abstracts from rel-
evant conferences, such as the International Cachexia Conference.
Experts in the field will be contacted for unpublished and ongoing
trials to identify any additional literature related to the review.
Data collection and analysis
Selection of studies
Two review authors (MNK,SG)will independently screen the arti-
cles retrieved from the searches using the Rayyan online screening
tool (Elmagarmid 2014) and determine eligibility by reading the
abstract of each study identified by the search. Independent review
authors will eliminate studies that clearly do not satisfy inclusion
criteria, and obtain full copies of the remaining studies. Two re-
view authors (ZQS, AG) will read these studies independently to
select relevant studies, and in the event of disagreement, a third
author will adjudicate (AS). We will not anonymise the studies in
any way before assessment. We will include a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
chart in the full review which will show the status of identified
studies (Moher 2009) as recommended in Part 2, Section 11.2.1
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of theCochrane Handbook (Higgins 2011).We will include studies
in the review irrespective of whether measured outcome data are
reported in a ‘usable’ way.
Data extraction and management
Two review authors (MNK, SG) will independently extract data
using a standard form and check for agreement before entry into
Review Manager (RevMan 2014). We will include information
about all the primary outcomes. We will collate multiple reports
of the same study, so that each study rather than each report is
the unit of interest in the review. We will collect characteristics
of the included studies in sufficient detail to populate a table of
‘Characteristics of included studies’ in the full review.
Assessment of risk of bias in included studies
This section is taken from the PaPaS template for protocols.
Two authors (MNK, PS) will independently assess risk of bias
for each study, using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and
adapted from those used by the Cochrane Pregnancy and Child-
birth Group, with any disagreements resolved by discussion. We
will complete a ’Risk of bias’ table for each included study using
the ’Risk of bias’ tool in RevMan (RevMan 2014).
We will assess the following for each study.
• Random sequence generation (checking for possible
selection bias): We will assess the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated). Studies using a non-random process
(e.g. odd or even date of birth; hospital or clinic record number)
will be excluded.
• Allocation concealment (checking for possible selection
bias): The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We will assess the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes); unclear risk
of bias (method not clearly stated).
• Blinding of participants and personnel (checking for
performance bias): We will assess the methods used to blind
study participants and personnel about the receipt of the
intervention. We will assess the methods as: low risk of bias
(study states that it was blinded and describes the method used
to achieve blinding); unclear risk of bias (study states that it was
blinded but does not provide an adequate information of how it
was done); high risk of bias (no blinding or incomplete blinding,
and the outcome is likely to be influenced by lack of blinding; or
blinding of participants of the study and personnel was
attempted, but it is likely that the blinding could have been
broken).
• Blinding of outcome assessment (checking for possible
detection bias): We will assess the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We will assess the methods
as: low risk of bias (study states that it was blinded and describes
the method used to achieve blinding, e.g. identical tablets;
matched in appearance and smell); unclear risk of bias (study
states that it was blinded but does not provide an adequate
description of how blinding was achieved).
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data): We will assess the methods used to deal with
incomplete data as: low risk (< 10% of participants did not
complete the study and/or used ‘baseline observation carried
forward’ analysis); unclear risk of bias (used ’last observation
carried forward’ analysis); high risk of bias (used ’completer’
analysis).
• Size of study (checking for possible biases confounded by
small size). We will assess studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (< 50
participants per treatment arm).
• Selective outcome reporting (checking for reporting bias):
We will assess studies as being at low risk of bias (the study
protocol is available; or the study protocol is not available but the
study reported all expected and pre-specified outcomes); high
risk of bias (the study reported one or more outcomes of interest
incompletely); unclear risk of bias (the study provides insufficient
information to permit judgement of ‘low risk’ or ‘high risk’).
• Other bias: We will assess the study as: low risk of bias (the
study appears to be free of other sources of bias); unclear risk of
bias (there may be a risk of bias, but there is insufficient
information to judge whether risk of bias exists; or insufficient
evidence that a problem under consideration will introduce bias);
or high risk of bias (there is at least one important risk of bias).
Measures of treatment effect
We will use a fixed-effect model or random-effects model to esti-
mate the overall direction, size and consistency of an effect. For
dichotomous variables, we will compute treatment effects as risk
ratios (RR) or odds ratios (OR) with 95% confidence intervals
(CI). For continuous data we will use mean differences (MD) with
95% CI when the results are measured in the same way in dif-
ferent studies. We will use standardised mean differences (SMD)
when the results obtained are conceptually the same but used dif-
ferent measurement scales. We will record means and standard
deviations. The mean change in each group will be obtained by
subtracting the final mean from the baseline mean. The change
in standard deviation will be obtained from CI, standard errors,
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t values, P values or F values (whichever is available) using the
RevMan calculator. When there is not enough information avail-
able to calculate the standard deviations for the changes, they will
be imputed. If the required data are not available, then we will use
a comparison of final measurements. We will evaluate the direc-
tion and size of the effect as well as looking at the consistency of
the effect across the selected studies. Clinically meaningful change
will be considered taking into account the change in weight and
appetite with a measurable entity and time span.
Unit of analysis issues
In parallel-group randomised controlled trials, we will consider
the individual patient as the unit of analysis. When incorporating
cross-over trials into a meta-analysis, we will follow the approach
suggested by Elbourne (Elbourne 2002).Wewill incorporate these
trials by taking measurements from experimental intervention pe-
riods and measurements from control intervention periods and
analysing these as if the trial were a parallel group trial of inter-
vention versus control. If carry-over is thought to be a problem,
we will include only data from the first period. The effect estimate
of cross-over trials will be included in a meta-analysis using the
generic inverse-variance method.
Dealing with missing data
We will carry out an intention-to-treat analysis. When published
data are missing, incomplete or inconsistent with RCT protocols,
we will ask for further information from the authors/manufactur-
ers. We will contact authors by email if studies did not report the
outcome measures of interest, did not describe randomisation or
intention-to-treat analysis or had missing data.
Assessment of heterogeneity
We plan to assess clinical heterogeneity by using the Chi2 test (P
value < 0.10 for statistical significance) and use the I2 statistic to
quantify heterogeneity. Heterogeneity will be regarded as consid-
erable if I2 is more than 75%; substantial if it is between 50%
and 90%; moderate if it is between 30% and 60% and mild if less
than 40% (Higgins 2011). If we identify statistical heterogeneity
(I² greater than, or equal to 50%), we will report it and explore
possible causes by prespecified subgroup analysis, and will apply a
random-effects model.
Assessment of reporting biases
If there are 10 or more included studies, we plan to conduct a fun-
nel plot test for asymmetry to assess for any evidence of reporting
bias. Additionally, possible sources of asymmetry in a funnel plot
will be explored.
Data synthesis
We will undertake a meta-analysis only if participants, interven-
tions, comparisons and outcomes are judged to be sufficiently sim-
ilar to ensure an answer that is clinically meaningful and relevant.
For analysis, we plan to use RevMan 2014, the statistical package
provided by the Cochrane Collaboration.
If statistical heterogeneity (I² greater than, or equal to 50%) is de-
tected, we will attempt to identify the sources of the heterogeneity
and will perform subsequent meta-analysis using a random-effects
model. If the meta-analysis is inappropriate for any other reason,
we will not pool the results of the included studies, but will present
a qualitative description of these studies with supporting tables.
If there are sufficient and homogeneous data with consistent or
comparable outcomes, we plan to perform a meta-analysis using
a fixed-effect model.
‘Summary of findings’ tables
We will include a ’Summary of findings’ (SoF) table as set out
in the PaPaS author guide (AUREF 2012) and recommended in
the Cochrane Handbook, chapter 4.6.6 (Higgins 2011). We will
present the SoF tables under the following comparisons for all of
the primary outcomes:
1. Ghrelin versus placebo;
2. Ghrelin versus an alternative experimental treatment
modality; and
3. Ghrelin in combination with other treatments versus
ghrelin treatment alone.
Two review authors (ZQS, MNQ) will assess the overall quality
of the evidence for each outcome using the GRADE system (
GRADEproGDT2015) andpresent the findings in the ’Summary
of findings’ tables. In particular, we will include key information
concerning the quality of evidence, the magnitude of effect of the
interventions examined, and the sum of available data on themain
outcomes.
We will decrease the grade if there is:
• A serious (-1) or very serious (-2) limitation to study quality;
• Important inconsistency (-1);
• Some (-1) or major (-2) uncertainty about directness;
• Imprecise or sparse data (-1);
• High probability of reporting bias (-1).
We will justify all decisions to down-grade the quality of studies
using footnotes.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses are planned for form, dose, duration and route
of administration of ghrelin, and for different types of cancer.
A C K N OW L E D G E M E N T S
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A P P E N D I C E S
Appendix 1. Appendix. MEDLINE search strategy
Database:OvidMEDLINE(R) In-Process&OtherNon-IndexedCitations andOvidMEDLINE(R) <1946 toPresent> Search Strategy:
1 Ghrelin/
2 (ghrelin or ppghrelin or (motilin adj2 peptide) or ghrl or obestatin or ppmtlrp or “appetite regulating hormone” or Anamorelin or
Ipamorelin or Eganamorelin or Hexarelin or MK-677 or Rikkunshito).tw.
3 Cachexia/
4 cachexia.tw.
5 cachexic.tw.
6 (weight or underweight or malnutrition or wasting).tw.
7 Weight Loss/
8 or/3-7
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9 exp Neoplasms/
10 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or choricarcinoma* or leukemia* or
leukaemia* or metastat* or sarcoma* or teratoma*).tw.
11 or/9-10
12 1 or 2
13 8 and 11 and 12
C O N T R I B U T I O N S O F A U T H O R S
MNK and ZQS designed and developed the protocol with input from AG, SG, PS, RK and AS. MNK and SG developed the search
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responsible for data extraction in the full review. All authors will be responsible for completing the protocol, full review, and updating
the review in future.
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